NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

Related Keywords

Boston ,Massachusetts ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Israel , ,Linkedin ,Company Investigational New Drug ,Twitter ,Prnewswire Neurosense Therapeutics Ltd ,Drug Administration ,Nasdaq ,Neurosense Therapeutics Ltd ,European Union ,European Medicines Agency ,Neurosense Therapeutics ,Sense Therapeutics ,Investigational New Drug ,Orphan Drug Designation ,Massachusetts General Hospital ,Neuron Derived Exosomes ,Neurosense ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Clinical Trials Amp Medical Discoveries ,Fda Approval ,New Products Amp Services ,